Relenza (Zanamivir) News and Research

RSS
Relenza (zanamivir) is an anti-viral drug, for persons aged 7 years and older for the treatment of uncomplicated influenza illness. This product is approved to treat type A and B influenza, the two types most responsible for flu epidemics. Clinical studies showed that for the drug to be effective, patients needed to start treatment within two days of the onset of symptoms. The drug seemed to be less effective in patients whose symptoms weren't severe or didn't include a fever. Relenza is approved for preventive use, to decrease the risk of developing influenza illness, for persons aged 5 and older. Relenza is a powder that is inhaled twice a day for five days from a breath-activated plastic device called a Diskhaler for treatment of influenza. For preventive use to reduce the risk of getting influenza, Relenza is inhaled once daily for 10 to 28 days as prescribed by a healthcare provider.
Research finds Tamiflu and Relenza relatively safe for use in pregnancy

Research finds Tamiflu and Relenza relatively safe for use in pregnancy

90 per cent of the world's population won't have access to antivirals in pandemic - generic drugs may help though

90 per cent of the world's population won't have access to antivirals in pandemic - generic drugs may help though

Scientists map sequence mutations of the 2009 H1N1 influenza A virus

Scientists map sequence mutations of the 2009 H1N1 influenza A virus

Experts warn of dangers of swine flu with almost 10,000 now infected, forecasts 4.9 billion doses needed

Experts warn of dangers of swine flu with almost 10,000 now infected, forecasts 4.9 billion doses needed

Simple interventions could contain flu spread – focus on children

Simple interventions could contain flu spread – focus on children

Swine flu could come round again!

Swine flu could come round again!

Panic buying of flu drug results in rationing

Panic buying of flu drug results in rationing

HIV-positive people worldwide at increased risk of the H1N1 flu

HIV-positive people worldwide at increased risk of the H1N1 flu

Warning on fraudulent 2009 H1N1 influenza products

Warning on fraudulent 2009 H1N1 influenza products

Research model shows best way to deal with a flu pandemic

Research model shows best way to deal with a flu pandemic

Sebelius, Obama take action on swine flu

Sebelius, Obama take action on swine flu

So far Australia clear of swine flu

So far Australia clear of swine flu

Flu pandemic long overdue

Flu pandemic long overdue

Swine flu pandemic threat puts the world on high alert

Swine flu pandemic threat puts the world on high alert

Hovione's TwinCaps inhaler in phase III trials for influenza

Hovione's TwinCaps inhaler in phase III trials for influenza

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

New drug targets main culprit in common colds

New drug targets main culprit in common colds

Discovery of new drug candidates to combat bird flu

Discovery of new drug candidates to combat bird flu

Bird flu pandemic would require multi-drug approach

Bird flu pandemic would require multi-drug approach

Another outbreak of bird flu in Seoul - all poultry in the city culled

Another outbreak of bird flu in Seoul - all poultry in the city culled